Skip to Main Content

Paper Details

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Am J Hematol
3
2023
Author NameAffiliation
Farhad RavandiThe University of Texas, MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas, MD Anderson Cancer Center
Hagop KantarjianThe University of Texas, MD Anderson Cancer Center
Gautam BorthakurThe University of Texas, MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2